 |
|
|
| |
Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR12 Interim Analysis
|
| |
| |
Reported by Jules Levin
2012 CROI Seattle, WA
Douglas T. Dieterich1, Vincent Soriano2, Kenneth E. Sherman3, Pierre-Marie Girard4, Jurgen K. Rockstroh5, Joshua Henshaw6, Raymond Rubin6, Mohammad Bsharat6, Nathalie Adda6, Mark S. Sulkowski7
On behalf of the Study 110 Team
1Mount Sinai School of Medicine, New York, NY, United States, 2Hospital Carlos III, Madrid, Spain, 3University of Cincinnati College of Medicine, Cincinnati, OH, United States, 4Hopital St Antoine, Paris, France, 5University of Bonn, Bonn, Germany, 6Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States, and 7Johns Hopkins University School of Medicine, Baltimore, MD, United States.
·Higher SVR12 rates were observed in chronic genotype 1 HCV/HIV co-infected patients treated with telaprevir combination treatment
-T/PR 74%
-PR 45%
·Telaprevir exposures were comparable across ART regimens
·In patients treated with telaprevir combination treatment, overall safety and tolerability profile was comparable to that previously observed in chronic genotype 1 HCV mono-infected patients
|
| |
|
|
|
|
|
